The rarity of these SCLC genotypes translates to a poor understanding of its biology and contributes to an ongoing debate on whether SCLC patients with RAF‐MEK‐ERK pathway activation can benefit from targeted therapies (Cristea and Sage, 2016). Here, MAP2K7 is linked to small cell lung carcinoma.